DURECT Corporation Invites You to Join a Conference Call Today Regarding its POSIDUR(TM) Collaboration with Hospira

News provided by

Jun 07, 2010, 04:10 ET

CUPERTINO, Calif., June 7 /PRNewswire-FirstCall/ -- In conjunction with the announcement of a POSIDUR™ (SABER™-Bupivacaine) collaboration between DURECT Corporation (Nasdaq: DRRX) and Hospira, Inc. (NYSE: HSP), you are invited to listen to a conference call that will be broadcast live over the internet on Monday, June 7, 2010 at 5:00 pm Eastern Time (2:00 pm Pacific Time).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation